The trial of clarification of the mechanism of salivary hypofunction involved in cancer therapies and development the care for protection of salivary glands by producing a model mouse.
Project/Area Number |
16K15863
|
Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
Allocation Type | Multi-year Fund |
Research Field |
Fundamental nursing
|
Research Institution | Yamagata University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
関亦 正幸 福島県立医科大学, 医学部, 准教授 (80250190)
野川 宏幸 千葉大学, 大学院理学研究院, 准教授 (40143250)
|
Research Collaborator |
NOGAWA Hiroyuki
INOUE Naokazu
YOSHIDA Daiki
HAYASAKA Yuto
SUINA Yumi
|
Project Period (FY) |
2016-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Keywords | 唾液腺 / 唾液分泌低下 / 放射線療法 / がん化学療法 / がん支持療法 / 口腔トラブル / 耳下腺 / アミラーゼ / 唾液分泌 / 初代培養細胞 / 遺伝子改変マウス / 有害事象予防ケア / 唾液線体外培養 |
Outline of Final Research Achievements |
Hyposalivation as a consequence of cancer therapies is the significant complication, because hyposalivation causes various side effects such as oral trouble, reducing illness motivation, including danger of life. This study aimed at clarification of the mechanism of salivary hypofunction involved in cancer therapies and development the care for protection of salivary glands, by producing a transgenic mouse introduced Venus gene which is enabled visualization and quantification of saliva secretion. We successfully produced the transgenic mouse and in vitro salivary gland culture-systems in this study. In future, we would like to contribute to the development of supporting treatments for cancer therapies by the identification of protectants for salivary glands and promoters for saliva secretion using the transgenic mouse and the culture systems.
|
Report
(3 results)
Research Products
(9 results)